Ranbaxy likely to post PAT at Rs 140 cr in Q3

39933 Investors following Ranbaxy Labs. Share this News with them.

0

Like this story, share it with millions of investors on M3

Ranbaxy likely to post PAT at Rs 140 cr in Q3

Pharmaceutical firm Ranbaxy Labs is expected to report a profit after tax of Rs 140 crore in the third quarter of 2011 as against Rs 308 crore in a year ago period.

Post your opinion here

 

0

Tweet

Share on Tumblr

ALSO READ News and Notices about Ranbaxy Labs See interviews with Ranbaxy Labs Management See what other Experts & Brokerages are saying about Ranbaxy Labs See previous Results of Ranbaxy Labs

Pharmaceutical firm Ranbaxy Labs is expected to report a profit after tax of Rs 140 crore in the third quarter of 2011 as against Rs 308 crore in a year ago period.

Revenues are seen going up 8% to Rs 2,091 crore versus Rs 1,935 crore during the same period.

EBITDA is likely to jump 28% to Rs 177 crore in July-September quarter of 2011 versus Rs 139 crore in the corresponding quarter of last fiscal.

Operating profit margin is expected to be at 8.5% versus 7% year-on-year. 

Important quarter for Ranbaxy - more focus on Lipitor generic commentary than on numbers